MAP2K1 mutation	Non Small Cell Lung Cancer	MAP2K1 mutation	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3	lorlatinib Resistant: C3 – Early Trials lorlatinib Resistant : C3
MAP2K1 mutation	Melanoma	MAP2K1 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
MAP2K1 mutation	Biliary Tract Cancer	MAP2K1 mutation	Biliary Tract Cancer	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
MAP2K1 mutation	Lung Non-Squamous Non-Small Cell Cancer	MAP2K1 mutation	Lung Non-Squamous Non-Small Cell Cancer	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3	binimetinib Sensitive: C3 – Early Trials binimetinib Sensitive : C3
MAP2K1 mutation	Pancreatic Ductal Adenocarcinoma	MAP2K1 mutation	Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3	avelumab + binimetinib Sensitive: C3 – Early Trials avelumab + binimetinib Sensitive : C3
MAP2K1 mutation	Ovarian Cancer	MAP2K1 mutation	Ovarian Cancer	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4	selumetinib Sensitive: C4 – Case Studies selumetinib Sensitive : C4
MAP2K1 mutation	Melanoma	MAP2K1 mutation	Melanoma	dabrafenib Resistant: D – Preclinical dabrafenib Resistant : D	dabrafenib Resistant: D – Preclinical dabrafenib Resistant : D
MAP2K1 mutation	Melanoma	MAP2K1 mutation	Melanoma	trametinib Resistant: D – Preclinical trametinib Resistant : D	trametinib Resistant: D – Preclinical trametinib Resistant : D
MAP2K1 mutation	Melanoma	MAP2K1 mutation	Melanoma	DS03090629 Sensitive: D – Preclinical DS03090629 Sensitive : D	DS03090629 Sensitive: D – Preclinical DS03090629 Sensitive : D

MAP2K1 mutation

Associations